S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

LXRX Lexicon Pharmaceuticals Inc

2.07

0.06 (2.99%)

19 Oct 2024 - Closed

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Sep 2024 to Oct 2024

Click Here for more Lexicon Pharmaceuticals Charts.

Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Oct 2023 to Oct 2024

Click Here for more Lexicon Pharmaceuticals Charts.

Lexicon Pharmaceuticals Inc News

Form 8-K - Current report
Thursday 17 October 2024 (3 days ago) • Edgar (US Regulatory)

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe
Thursday 17 October 2024 (3 days ago) • GlobeNewswire Inc.

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe
Thursday 17 October 2024 (3 days ago) • PR Newswire (US)

Form 3 - Initial statement of beneficial ownership of securities
Tuesday 8 October 2024 (2 weeks ago) • Edgar (US Regulatory)

Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
Friday 27 September 2024 (3 weeks ago) • GlobeNewswire Inc.

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer
Monday 16 September 2024 (1 month ago) • GlobeNewswire Inc.

Form 8-K - Current report
Monday 16 September 2024 (1 month ago) • Edgar (US Regulatory)

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
Tuesday 10 September 2024 (1 month ago) • GlobeNewswire Inc.

Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences
Wednesday 4 September 2024 (2 months ago) • GlobeNewswire Inc.

New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA® (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration
Tuesday 3 September 2024 (2 months ago) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Friday 16 August 2024 (2 months ago) • Edgar (US Regulatory)

Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio
Tuesday 13 August 2024 (2 months ago) • GlobeNewswire Inc.

More Lexicon Pharmaceuticals Inc News Articles

Australia And New Zealan...

Sterling vs AUD

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions